<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Bar-Or, Amit</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">RPC1063 Safe and Effective in RRMS</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">12-13</style></pages><abstract><style  face="normal" font="default" size="100%">Treatment with the sphingosine 1-phosphate (S1P) receptor modulator, RPC1063, resulted in a substantial decrease in gadolinium-enhancing (Gd+) lesions and the number of new or enlarging T2 lesions in patients with relapsing-remitting multiple sclerosis (RRMS). This article presents data from the Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients trial [Radiance Study; NCT01628393].</style></abstract><number><style face="normal" font="default" size="100%">29</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>